Plevy, Scott <br/><br/>
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.  [electronic resource] 

 -  Gastroenterology  Nov 2007 
 - 1414-22 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0012 
<br/><br/><label>Standard No.: </label>10.1053/j.gastro.2007.08.035  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>CD3 Complex--immunology<br/>CD4-Positive T-Lymphocytes--pathology<br/>CD8-Positive T-Lymphocytes--pathology<br/>Colitis, Ulcerative--drug therapy<br/>Dose-Response Relationship, Drug<br/>Endoscopy, Gastrointestinal<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Severity of Illness Index